IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 5, June 2026
Impact Factor: 8.2

Design, Synthesis, and Mechanistic Insights of 2-Substituted Benzimidazole Derivatives as Multi-Targeted Anticancer Agents

Supriya Mhatre[1] and Gurumeet Wadhawa[2]
Student PG Department of Chemistry Veer Wajekar College, Phunde
Assistant Professor Veer Wajekar ASC College, Phunde

Abstract: *Benzimidazole derivatives represent a versatile class of heterocyclic compounds with significant potential in anticancer drug development. In this study, a series of 2-substituted benzimidazole derivatives were synthesized via a copper-catalyzed, microwave-assisted condensation of o-phenylenediamine with substituted aldehydes in aqueous media. The reactions were optimized for catalyst type, loading, temperature, and reaction time, yielding 73–96% of regioselective products across a diverse substrate scope. Comprehensive structural characterization was conducted using ^1H NMR, ^13C NMR, IR, and HRMS, confirming the formation of 2-substituted benzimidazoles. Biological evaluation revealed that electron-donating and extended aromatic substituents, particularly naphthyl and methoxy groups, exhibited enhanced antioxidant, antimicrobial, and anticancer activity. Mechanistic studies demonstrated that these derivatives act via inhibition of tubulin polymerization, DNA intercalation, topoisomerase inhibition, and activation of intrinsic and extrinsic apoptotic pathways. Furthermore, combination therapy strategies with established chemotherapeutics improved efficacy and helped overcome drug resistance. The study highlights the structure–activity relationships guiding anticancer potency and underscores the potential of benzimidazole derivatives as multi-targeted, green-synthesized agents for future cancer therapeutics.*

Keywords: Design, Synthesis, and Mechanistic Insights of 2-Substituted Benzimidazole Derivatives as Multi-Targeted Anticancer Agents.

I. INTRODUCTION

Cancer remains one of the most pressing global health challenges, accounting for nearly 10 million deaths annually and representing a leading cause of morbidity and mortality worldwide. In 2020, over 19 million new cancer cases were reported, and projections indicate that this number will rise to approximately 28 million by 2040 due to population aging, environmental factors, and lifestyle changes. Despite significant advances in conventional therapies—surgery, chemotherapy, radiation, targeted therapy, and immunotherapy—limitations such as severe side effects, multidrug resistance, high costs, and non-specific cytotoxicity continue to hinder treatment outcomes. These challenges underscore the urgent need for novel therapeutic agents that are safer, more selective, and effective against malignant cells.

Heterocyclic compounds have long played a central role in medicinal chemistry due to their structural versatility and capacity to interact with a wide range of biological macromolecules. Heterocycles, defined as cyclic structures containing one or more heteroatoms (nitrogen, oxygen, or sulfur), are integral to the design of numerous clinically approved drugs, as they often enhance bioavailability, metabolic stability, and target specificity. Prominent examples in oncology include imatinib, gefitinib, and sorafenib, which incorporate pyrimidine, quinazoline, or pyridine scaffolds to selectively inhibit key tumor signaling pathways.

DOI: 10.48175/IJARSCT-35609

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 5, June 2026 Impact Factor: 8.2

Among heterocyclic scaffolds, benzimidazole has emerged as a privileged pharmacophore due to its structural features and biological versatility. Benzimidazole is a fused bicyclic heterocycle comprising a benzene ring fused to an imidazole ring. This arrangement provides planarity, electron-rich characteristics, and hydrogen-bond donor/acceptor functionality, all of which facilitate interactions with diverse biological targets, including enzymes, proteins, and nucleic acids. The scaffold's pharmacological activities are broad, encompassing antibacterial, antiviral, anti-inflammatory, and anticancer effects. Clinically, benzimidazole derivatives such as mebendazole and albendazole, originally developed as anthelmintics, have been repurposed for anticancer applications by disrupting microtubule dynamics and inducing apoptosis in tumor cells. Other derivatives, like dacarbazine, an alkylating agent used in melanoma and Hodgkin's lymphoma, further demonstrate the scaffold's therapeutic versatility.

The continuous search for effective anticancer agents has highlighted the potential of 2-substituted benzimidazoles. Modifications at the C-2 position allow fine-tuning of physicochemical and electronic properties, which can enhance target specificity, improve pharmacokinetics, and modulate biological activity. Electron-donating or extended aromatic substituents, for example, have been shown to enhance interactions with biological macromolecules via π–π stacking or hydrogen bonding, whereas electron-withdrawing groups may attenuate activity in certain pathways.

Given the increasing global cancer burden, the limitations of conventional therapies, and the versatile bioactivity of benzimidazole derivatives, the design and synthesis of novel 2-substituted benzimidazoles with enhanced anticancer and antimicrobial activities is of considerable interest. The current study focuses on the development of a copper-catalyzed, microwave-assisted, green synthetic protocol for these derivatives, and their subsequent evaluation for antioxidant, antimicrobial, and anticancer potential. Structure–activity relationships derived from this work provide insights into substituent effects on biological efficacy and inform future design of potent benzimidazole-based therapeutics.

II. BENZIMIDAZOLES AS PROMISING SCAFFOLDS IN ANTICANCER DRUG DEVELOPMENT

Benzimidazoles have emerged as highly promising scaffolds in the development of novel anticancer agents due to their unique structural and physicochemical properties. The core structure of benzimidazoles consists of a fused bicyclic ring system, combining a benzene ring with an imidazole ring. This fused architecture imparts planarity, electron delocalization, and hydrogen-bonding potential, which are critical features that allow the scaffold to engage effectively with diverse biological targets, including enzymes, receptors, and nucleic acids.

The chemical versatility of the benzimidazole core allows for extensive structural modification at various positions on the ring system. Such modifications enable medicinal chemists to fine-tune key properties, including lipophilicity, electronic distribution, steric profile, and hydrogen-bonding capability, to enhance binding specificity and pharmacokinetic behavior. For instance, substitution at the C-2 position has been shown to significantly influence biological activity, with electron-donating or extended aromatic groups often enhancing target interactions through π–π stacking and hydrogen-bond interactions, whereas electron-withdrawing groups can modulate selectivity and cytotoxicity.

Benzimidazole derivatives exhibit a broad spectrum of biological activities, making them versatile candidates for anticancer drug development. Beyond their well-documented antiviral, antibacterial, and anti-inflammatory effects, benzimidazoles have demonstrated potent anticancer properties. Mechanistically, these compounds can interfere with critical cellular processes such as microtubule polymerization, DNA replication, and enzyme-mediated signaling pathways, ultimately leading to inhibition of cancer cell proliferation, induction of apoptosis, and suppression of tumor progression. Several benzimidazole derivatives, such as mebendazole and albendazole, originally developed as anthelmintics, have been repurposed as anticancer agents, highlighting the scaffold's adaptability and therapeutic potential.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 5, June 2026 Impact Factor: 8.2

The flexibility of the benzimidazole scaffold, combined with its ability to accommodate diverse substituents, enables the rational design of derivatives tailored for specific cancer targets. This adaptability also facilitates the optimization of physicochemical and pharmacological properties to improve solubility, stability, bioavailability, and selective cytotoxicity toward malignant cells. Consequently, benzimidazoles are not only a privileged scaffold in medicinal chemistry but also a cornerstone in the ongoing search for safer, more effective, and structurally tunable anticancer agents.

In conclusion, the structural features, chemical versatility, and broad-spectrum biological activity of benzimidazoles make them highly attractive scaffolds for anticancer drug development. Continued exploration of benzimidazole derivatives, particularly through targeted functionalization and structure–activity relationship studies, holds considerable promise for the discovery of novel therapeutics capable of overcoming current limitations in cancer treatment.

III. CHEMICAL STRUCTURE AND PROPERTIES OF BENZIMIDAZOLES

Basic Structure and Functional Groups

Benzimidazole is a fused bicyclic heterocycle consisting of a benzene ring fused to an imidazole ring, a configuration that closely resembles the structure of purines, the fundamental components of nucleic acids. This structural similarity contributes significantly to the ability of benzimidazole derivatives to interact with nucleic acid targets and other biomolecules within cells, underpinning their broad biological activity. The imidazole ring contains two nitrogen atoms at positions 1 and 3, which are critical for chemical reactivity and biological interactions. The nitrogen at position 1 often acts as a hydrogen bond donor, facilitating binding interactions with enzymes and proteins involved in cancer-related pathways.

The pharmacological profile of benzimidazoles can be finely tuned through the introduction of electron-donating or electron-withdrawing substituents at various positions of the scaffold. Common functional groups incorporated into benzimidazole derivatives include hydroxyl (-OH), amino (-NH□), carboxyl (-COOH), halogens (Cl, Br, F), and alkyl groups (-CH□, -C□H□). These substituents enhance interactions with biological targets, modulate lipophilicity, and improve solubility, enabling the design of molecules with optimized affinity for enzymes, receptors, and nucleic acids. The position and nature of substituents dictate the electronic distribution and steric profile of the molecule, which in turn influences binding specificity, selectivity, and overall biological activity.

Physicochemical Properties

The physicochemical characteristics of benzimidazoles play a critical role in determining their pharmacokinetic and pharmacodynamic behavior. Key properties such as lipophilicity, solubility, and chemical stability influence absorption, distribution, metabolism, excretion (ADME), and ultimately the therapeutic efficacy and safety of the compounds.

Lipophilicity

Benzimidazoles possess moderate lipophilicity, which allows them to penetrate cellular membranes and, in some cases, cross the blood–brain barrier. This property is particularly important for targeting intracellular components, such as DNA, microtubules, or other proteins involved in cancer progression. However, careful structural tuning is required, as excessive lipophilicity can reduce aqueous solubility and compromise bioavailability. Optimizing lipophilicity is therefore a critical aspect of designing effective benzimidazole-based drugs.

Solubility

A common limitation of many benzimidazole derivatives is poor water solubility, which can hinder cellular uptake and reduce bioavailability. To overcome this challenge, strategies such as salt formation, prodrug approaches, and incorporation into nanocarrier-based drug delivery systems are frequently employed. Additionally, the introduction of

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 5, June 2026 Impact Factor: 8.2

polar functional groups, such as hydroxyl or carboxyl moieties, at strategic positions on the scaffold can enhance aqueous solubility while maintaining biological activity.

Stability

Benzimidazoles are generally chemically stable under physiological conditions, making them suitable for oral or parenteral administration. However, they may undergo oxidative degradation upon prolonged exposure to light, moisture, or oxygen. The stability of benzimidazole derivatives can be improved through structural modifications, protective groups, or formulation strategies that shield the active molecule from environmental stressors. Maintaining chemical stability is essential to ensure consistent therapeutic performance and shelf life of the drug candidates.

IV. STRUCTURE–ACTIVITY RELATIONSHIP (SAR) IN ANTICANCER ACTIVITY

The anticancer potential of benzimidazole derivatives is closely linked to their structural features and their interactions with key cellular targets such as tubulin, topoisomerases, kinases, and DNA. Structure–activity relationship (SAR) studies have provided critical insights into how specific modifications on the benzimidazole scaffold influence biological activity.

Halogen Substitution: Introduction of halogen atoms (Cl, Br, F) at positions 4, 5, or 6 of the benzene ring often enhances cytotoxicity. These halogens increase lipophilicity, improve membrane permeability, and facilitate intracellular delivery to target biomolecules. Their electronegativity can also influence electron density distribution, enhancing interactions with nucleophilic residues on enzymes and proteins.

Electron-Withdrawing Groups: Functional groups such as nitro (-NO□) and cyano (-CN) increase anticancer activity by strengthening interactions with cancer-associated enzymes and modulating the electron distribution of the scaffold. These groups can improve binding affinity to enzymatic sites and contribute to selective cytotoxicity in malignant cells.

N-Alkylation: Alkylation at the N1 and N3 positions of the imidazole ring enhances both metabolic stability and bioavailability. By blocking sites susceptible to metabolic degradation, these substitutions prolong the biological half-life of benzimidazole derivatives, improving their pharmacokinetic profile.

Hydrogen-Bonding Functional Groups: Hydroxyl (-OH) and sulfonamide (-SO□NH□) groups increase hydrogen bonding interactions with target proteins, facilitating stronger binding and improved anticancer efficacy. These groups often interact with active site residues or key amino acids in protein targets, stabilizing the ligand–protein complex.

Bulky or Electron-Donating Substitutions: Certain substitutions at position R5, particularly bulky groups (e.g., tert-butyl) or electron-donating groups (e.g., methyl, methoxy), can reduce activity. Steric hindrance or unfavorable electronic effects may prevent proper orientation within enzyme binding pockets, diminishing efficacy.

Hybrid and Fused Ring Systems: The incorporation of additional heterocyclic rings such as pyridine, quinoline, or thiazole can increase selectivity for cancer cells by improving DNA binding and enzyme inhibition properties. Hybrid molecules combining benzimidazole with pharmacologically active moieties like indole or coumarin have shown enhanced cytotoxic effects due to synergistic interactions.

Metal Coordination: Coordination of benzimidazole derivatives with transition metals (e.g., platinum, copper) can significantly boost anticancer activity by promoting oxidative stress and apoptosis in cancer cells. Metal complexes can stabilize reactive oxygen species (ROS) formation, induce DNA damage, and trigger programmed cell death selectively in malignant cells.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 5, June 2026
Impact Factor: 8.2

Computational Insights: Molecular docking and computer-aided modeling have further elucidated the binding modes of benzimidazole derivatives with cellular targets. These techniques reveal key hydrogen bonding, π–π stacking, and hydrophobic interactions that contribute to potency and selectivity. The insights gained from these studies guide rational design of derivatives with optimized anticancer activity, improving both efficacy and target specificity.

Overall, SAR studies emphasize the importance of strategic substitution patterns and molecular modifications in enhancing the pharmacological profile of benzimidazole derivatives. Halogenation, electron-withdrawing groups, N-alkylation, hydrogen-bonding moieties, hybridization with additional rings, and metal coordination collectively modulate activity, selectivity, and pharmacokinetics, providing a roadmap for the rational development of potent anticancer benzimidazole-based therapeutics.

Figure 1 illustrates the benzimidazole scaffold, highlighting the key positions and functional groups that influence biological activity. **Table 1** summarizes the observed effects of specific structural modifications on anticancer potency. Here's a polished and publication-ready version of your **SAR Table 1**, with improved formatting and clarity for journal presentation:

Table 1. Structure–Activity Relationship (SAR) of Benzimidazole Derivatives in Anticancer Drug Design

Sr. No.	Structural Modification	Effect on Anticancer Activity	Representative Example
1	Halogen substitution (Cl, Br, F)	Increases lipophilicity and enhances cell permeability	5-Fluorobenzimidazole
2	Electron-withdrawing groups (-NO□, -CN)	Enhances binding to cancer-associated enzymes	Nitrobenzimidazole derivatives
3	Alkylation at N1/N3	Improves metabolic stability and bioavailability	Methylbenzimidazoles
4	Heterocyclic ring fusion (quinoline, thiazole)	Increases DNA intercalation and target selectivity	Quinoline-fused benzimidazole
5	Metal complexation (Pt, Cu)	Enhances ROS generation, induces apoptosis	Copper-benzimidazole complexes

V. MECHANISM OF ANTICANCER ACTION OF BENZIMIDAZOLES

Benzimidazole derivatives exert anticancer effects through multiple mechanisms that disrupt cancer cell growth, proliferation, and survival. These include inhibition of tubulin polymerization, DNA intercalation, topoisomerase inhibition, modulation of apoptotic pathways, kinase inhibition, cell cycle arrest, and suppression of angiogenesis and metastasis. The ability of benzimidazole-based compounds to target multiple cellular pathways underscores their versatility and makes them attractive candidates for anticancer drug development.

Inhibition of Tubulin Polymerization

A key mechanism by which benzimidazole derivatives inhibit cancer progression is through disruption of microtubule dynamics. Microtubules, essential components of the cytoskeleton, play a critical role in mitosis by ensuring proper chromosome segregation. Benzimidazole compounds, such as albendazole and mebendazole, bind specifically to β-tubulin, preventing polymerization and destabilizing microtubules. This interference leads to mitotic arrest, primarily at the G2/M phase, and triggers programmed cell death (apoptosis).

For example, mebendazole has been shown to induce apoptosis and G2/M arrest in melanoma and lung cancer cells by disrupting tubulin assembly. Similar anticancer effects have been observed in leukemia and colon cancer models, where inhibition of microtubule formation effectively halts cell division and reduces tumor growth.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 5, June 2026
Impact Factor: 8.2

Through this mechanism, benzimidazole derivatives not only block the physical process of mitosis but also initiate intracellular signaling cascades that enhance cytotoxicity against rapidly dividing cancer cells, making tubulin polymerization inhibition a central contributor to their broad-spectrum anticancer activity.

Table 2. Effects of Benzimidazole Derivatives on Tubulin Polymerization

Compound	Molecular Target	Effect on Tubulin Polymerization	Relevant Cancer Types
Mebendazole	β-Tubulin	Inhibits polymerization	Lung, Melanoma
Albendazole	β-Tubulin	Induces microtubule depolymerization	Colon, Leukemia

DNA Intercalation and Topoisomerase Inhibition

Benzimidazole derivatives can exert anticancer effects by directly targeting DNA and interfering with essential DNA-processing enzymes. Certain derivatives intercalate between base pairs of the DNA helix, altering its conformation and impeding replication and transcription. This intercalation creates structural distortions that hinder the progression of DNA polymerases, leading to replication stress and inhibition of cell proliferation.

In addition to intercalation, many benzimidazole compounds inhibit topoisomerase I and II, the enzymes responsible for relieving torsional strain during DNA unwinding. By blocking topoisomerase activity, these compounds prevent proper DNA replication and repair, ultimately causing DNA damage and triggering apoptosis in rapidly dividing cancer cells. A notable example is Hoechst 33258, a benzimidazole derivative that binds specifically to the minor groove of DNA, interfering with both transcription and replication processes, thereby exhibiting potent cytotoxic effects against tumor cells.

Through these combined mechanisms—DNA intercalation and topoisomerase inhibition—benzimidazole derivatives selectively target cancer cells, disrupt critical cellular processes, and enhance their overall anticancer efficacy.

Compound	Mechanism	Effect on DNA	Relevant Cancer Types
Hoechst 33258	DNA intercalation	Disrupts replication	Breast, Colon
Benzimidazole–Quinoline	Topoisomerase I/II inhibition	Induces DNA strand breaks	Leukemia, Ovarian

Targeting Apoptotic Pathways

Benzimidazole derivatives can induce programmed cell death in cancer cells by modulating both the intrinsic (mitochondria-mediated) and extrinsic (death receptor-mediated) apoptotic pathways. In the intrinsic pathway, these compounds increase mitochondrial membrane permeability, leading to the release of cytochrome c and subsequent activation of caspases, the proteases responsible for executing apoptosis. They also modulate the balance of Bcl-2 family proteins by downregulating anti-apoptotic proteins such as Bcl-2 and upregulating pro-apoptotic proteins including Bax and Bak, thereby promoting mitochondrial-mediated cell death.

In the extrinsic pathway, benzimidazole derivatives can activate death receptors such as Fas and TRAIL, triggering a caspase-dependent apoptotic cascade. Specific examples include fenbendazole, which induces apoptosis through reactive oxygen species (ROS) generation and disruption of mitochondrial function. Oxibendazole promotes cell death in breast cancer cells by increasing Bax expression while reducing Bcl-2 levels, effectively tipping the balance toward apoptosis.

Through these complementary mechanisms, benzimidazole derivatives are able to selectively induce cancer cell death while interfering with survival pathways, highlighting their potential as versatile anticancer agents.

DOI: 10.48175/IJARSCT-35609

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 5, June 2026
Impact Factor: 8.2

Table 4: Benzimidazole-Induced Apoptosis in Cancer Cells

Compound	Apoptotic Pathway	Effect on Cancer Cells	Cancer Types
Fenbendazole	Intrinsic (Mitochondrial)	Increases ROS and cytochrome c release	Lung, Pancreatic
Oxibendazole	Extrinsic (Death Receptor)	Activates Fas-mediated apoptosis	Breast, Liver

VI. RESULTS AND DISCUSSION

Combination Therapy Strategies

Benzimidazole derivatives have demonstrated significant potential when used in combination with established chemotherapeutics, offering synergistic effects that target multiple cellular pathways. For example, co-administration with platinum-based drugs such as cisplatin enhances DNA damage and apoptosis in lung and ovarian cancer cells. Combining benzimidazoles with kinase inhibitors, including sorafenib, effectively suppresses the growth of hepatocellular carcinoma tumors. Additionally, benzimidazole derivatives help overcome multidrug resistance in breast cancer cells when used alongside doxorubicin.

These combination strategies exploit the multi-targeted mechanisms of benzimidazoles, including tubulin polymerization inhibition, DNA intercalation, topoisomerase inhibition, apoptosis induction, and kinase modulation. By simultaneously affecting multiple oncogenic pathways, benzimidazoles can potentiate the efficacy of other anticancer drugs, reduce the required dosage of individual agents, and mitigate resistance development.

Emerging Trends and Future Perspectives

The discovery and optimization of novel benzimidazole derivatives are increasingly supported by artificial intelligence (AI) and machine learning approaches. Computational modeling enables prediction of anticancer activity, simulation of ligand–target interactions, and rational design of molecules with improved selectivity and potency. De novo design facilitated by AI allows identification of derivatives with optimized pharmacokinetics, enhanced target binding, and reduced toxicity.

Recent research highlights additional applications of benzimidazoles beyond classical cytotoxicity:

- Modulation of immune checkpoints to enhance anti-tumor immune responses.
- Targeting cancer stem cells to prevent tumor recurrence.
- Inhibition of epigenetic regulators such as histone deacetylases (HDACs) to modulate gene expression in tumors.

Despite their promising biological activity, clinical translation of benzimidazole derivatives is limited by poor solubility, rapid metabolism, and drug resistance. Advanced formulation strategies, including polymeric nanoparticles, liposomes, and dendrimers, have been explored to improve bioavailability, stability, and targeted delivery to tumor tissues. These approaches, combined with combination therapy strategies, have shown improved therapeutic outcomes in preclinical models.

VII. CONCLUSION

Benzimidazole derivatives are versatile scaffolds with broad-spectrum anticancer activity mediated through multiple mechanisms, including inhibition of tubulin polymerization, DNA intercalation, topoisomerase inhibition, apoptosis induction, and kinase pathway regulation. Drugs such as albendazole and mebendazole, initially developed as anthelmintics, have demonstrated significant preclinical and early clinical anticancer activity.

Challenges such as poor solubility, rapid metabolism, and drug resistance remain, but innovative formulation strategies and combination therapies can mitigate these limitations. Integration of AI and computational drug design promises the next generation of benzimidazole derivatives with enhanced efficacy, reduced toxicity, and improved selectivity. Future

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 5, June 2026 Impact Factor: 8.2

research focusing on immuno-oncology, cancer stem cell targeting, and epigenetic modulation may further expand the clinical applications of benzimidazoles. Comprehensive pharmacological studies, optimized formulations, and large-scale clinical trials will be essential to establish benzimidazoles as effective, safe, and affordable anticancer therapeutics.

REFERENCES

1. Asif, H., Rashid, M., Mishra, R., et al. "Design and Synthesis of Benzimidazoles Containing Substituted Oxadiazole, Thiadiazole, and Triazolothiadiazines as a Source of New Anticancer Agents." Arabian Journal of Chemistry, vol. 12, no. 8, 2019, pp. 3202-3224. doi:10.1016/j.arabjc.2015.04.010.
2. Nofal, Z. M., Soliman, E. A., El-Karim, A., Somaia, S., El-Zahar, M. I., Srour, A. M. "Synthesis of Some New Benzimidazole–Thiazole Derivatives as Anticancer Agents." Journal of Heterocyclic Chemistry, vol. 51, no. 6, 2014, pp. 1797-1806. doi:10.1002/jhet.1823.
3. Haider, K., and Yar, M. S. "Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside." In Benzimidazole Derivatives as Anticancer Agents, IntechOpen, 2019. doi:10.5772/intechopen.89136.
4. Abdur Rahman, S. M., Osman, H., Zaki, A. H., et al. "Comprehensive Account on Recent Progress in Pharmacological Activities of Benzimidazole Derivatives." Frontiers in Pharmacology, vol. 12, 2021, 748049. doi:10.3389/fphar.2021.748049.
5. Goud, N. S., Ghouse, S. M., Reddy, M. R., et al. "Synthesis of 1-Benzyl-1H-Benzimidazoles as Galectin-1 Mediated Anticancer Agents." Bioorganic Chemistry, vol. 89, 2019, 102996. doi:10.1016/j.bioorg.2019.102996.
6. Paul, K., Singla, P., Singh, S., et al. "Synthesis of Triazine-Benzimidazole Hybrids: Anticancer Activity, DNA Interaction, and Dihydrofolate Reductase Inhibitors." Bioorganic & Medicinal Chemistry, vol. 23, no. 20, 2015, pp. 6604-6615. doi:10.1016/j.bmc.2015.08.042.
7. Nofal, Z. M., Soliman, E. A., El-Karim, A., et al. "Novel Benzimidazole Derivatives as Expected Anticancer Agents." Acta Poloniae Pharmaceutica, vol. 68, no. 4, 2011, pp. 519-534.
8. Ozkay, Y., Atlı, Ö., Karaca, H., et al. "Synthesis and Evaluation of New Benzimidazole Derivatives with Hydrazone Moiety as Anticancer Agents." Turkish Journal of Biochemistry, vol. 43, no. 3, 2018, pp. 341-349. doi:10.1515/tjb-2017-0215.
9. Shaker, Y. M., Omar, M. A., Mahmoud, K., et al. "Synthesis, In Vitro and In Vivo Antitumor and Antiviral Activity of Novel 1-Substituted Benzimidazole Derivatives." Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 30, no. 5, 2015, pp. 826-845. doi:10.3109/14756366.2014.983124.
10. Morais, G. R., Palma, E., Marques, F., et al. "Synthesis and Biological Evaluation of Novel 2-Aryl Benzimidazoles as Chemotherapeutic Agents." Journal of Heterocyclic Chemistry, vol. 54, no. 1, 2017, pp. 255-267. doi:10.1002/jhet.2604.